Novel quinolines carrying pyridine, thienopyridine, isoquinoline, thiazolidine, thiazole and thiophene moieties as potential anticancer agents

Open access


As a part of ongoing studies in developing new anticancer agents, novel 1,2-dihydropyridine 4, thienopyridine 5, isoquinolines 6–20, acrylamide 21, thiazolidine 22, thiazoles 23–29 and thiophenes 33–35 bearing a biologically active quinoline nucleus were synthesized. The structure of newly synthesized compounds was confirmed on the basis of elemental analyses and spectral data. All the newly synthesized compounds were evaluated for their cytotoxic activity against the breast cancer cell line MCF7. 2,3-Dihydrothiazole-5-carboxamides 27, 25, 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide (34), 1,2-dihydroisoquinoline-7-carbonitrile (7), 5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (35), 1,2-dihydroisoquinoline-7-carbonitrile (6), 2-cyano-3-(dimethylamino)-N-(quinolin-3-yl)acrylamide (21), 1,2-dihydroisoquinoline-7-carbonitriles (11) and (8) exhibited higher activity (IC50 values of 27–45 μmol L–1) compared to doxorubicin (IC50 47.9 μmol L–1). LQ quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (12), 2-thioxo-2,3-dihydrothiazole-5-carboxamide (28) and quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (15) show activity comparable to doxorubicin, while (quinolin-3-yl)-1,2-dihydroisoquinoline-7-carbonitrile (9), 2,3-dihydrothiazole-5-carboxamide (24), thieno [3,4-c] pyridine-4(5H)-one (5), cyclopenta[b]thiophene-3-carboxamide (33) and (quinolin-3-yl)-6-stryl-1,2-dihydroisoquinoline-7-carbonitrile (10) exhibited moderate activity, lower than doxorubicin.

1. H. Frankish, 15 Million new cancer cases per year by 2020, says WHO, Lancet 361 (2003) 1278–1287; DOI: 10.1016/S0140-6736(03)13038-3.

2. K. Kubo, T. Shimizu, S. I. Ohyama, H. Murooka, A. Iwai, K. Nakamura, K. Hasegawa, Y. Kobayashi, N. Takahashi, K. Takahashi, S. Kato, T. Izawa and T. Isoe, Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N’-{4-(4-quinolyloxy)phenyl}-ureas, J. Med. Chem. 48 (2005) 1359–1366; DOI: 10.1021/jm030427r.

3. R. O’Connor, Mdm–mediated ubiquitylation: P53 and beyond, a review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance, Curr. Cancer Drug Targets 9 (2009) 273–280; DOI: 10.2174/156800909788166583.

4. C. Hu, V. R Solomon and G. L. Ulibarri, The efficacy and selectivity of tumor cell killing by AKT inhibitors are substantially increased by chloroquin, Bioorg. Med. Chem. 16 (2008) 7888–7893; DOI: 10.1016/j.bmc.2008.07.076.

5. Y. C. Mayur, G. J. Peters, V. V. Prasad, C. Lemo and N. K. Sathish, Design of new drug molecules to be used in reversing multidrug resistance in cancer, Curr. Cancer Drug Targets 9 (2009) 298–306; DOI: 10.2174/156800909788166619.

6. M. G. Ferlin, B. Gatto, G. Chiarelotto and M. Palumbo, Pyrroloquinoline derivatives as potential antineoplastic drugs, Bioorg. Med. Chem. 8 (2000) 1415–1422; DOI: 10.1016/S0968-0896(00)00060-2.

7. M. S. Alsaid, M. S. Bashandy, S. I. Al-Qasoumi and M. M. Ghorab, Anti-breast cancer activity of some novel 1,2-dihydropyridine, thiophene and thiazole derivatives, Eur. J. Med. Chem. 46 (2011) 137–141; DOI: 10.1016/j.ejmech.2010.10.024.

8. S. Pédeboscq, D. Gravier, F. Casadebaig, G. Hou, A. Gissot, F. De. Giorgi, F. Ichas, J. Cambar and J. P. Pometan, Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells, Eur. J. Med. Chem. 45 (2010) 2473–2479; DOI:10.1016/j.ejmech.-2010.02.032.

9. R. L. Weinkauf, A. Y. Chen, C. Yu, L. Liu, L. Barrows and E. J. LaVoie, Antineoplastic activity of benzimidazo[1,2-b] isoquinolines, indolo[2,3-b]quinolines, and pyridocarbazoles, Bioorg. Med. Chem. 2 (1994) 781–786; DOI: 10.1016/S0968-0896(00)82177-X.

10. S. Li, Z. Yao, Y. Zhao, W. Chen, H. Wang, X. Kuang, W. Zhan, S. Yao, S. Yu and W. Hu, Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase, Bioorg. Med. Chem. Lett. 22 (2012) 5279–5282; DOI: 10.1016/j.bmcl.2012.06.044.

11. F. E. Onen-Bayram, I. Durmaz, D. Scherman, J. Herscovici and R. Cetin-Atalay, A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells, Bioorg. Med. Chem. 20 (2012) 5094–5102; DOI: 10.1016/j.bmc.2012.07.016.

12. G. J. Atwell, C. D. Bos, B. C. Baguley and W. A. Denny, Potential antitumor agents. 56. “Minimal” DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides, J. Med. Chem. 3 (1988) 1048–1052; DOI: 10.1021/jm00400a029.

13. G. J. Atwell, B. C. Baguley and W. A. Denny, Potential antitumor agents. 57. 2-phenylquinoline-8-carboxamides as minimal DNA-intercalating antitumor agents with in vivo solid tumor activity, J. Med. Chem. 32 (1989) 396–401; DOI: 10.1021/jm00122a018.

14. T. Suzuki, N. Fukazawa, K. San-nohe, W. Sato, O. Yano and T. Tsuruo, Structure activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer, J. Med. Chem. 40 (1997) 2047–2052; DOI: 10.1021/jm960869l.

15. Y. H. Wang, T. Motoji, S. Motomura, N. Shiozaki, T. Tsuruo and H. Mizoguchi, Multi-drug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line, Eur. J. Haematol. 58 (1997) 186–194; DOI: 10.1111/j.1600-0609.1997.tb00946.x.

16. H. Zhao, Y. Cai, S. Santi, R. Lafrenie and H. Lee, Chloroquine-mediated radiosensitization is due to the destabilization of the lysosomal membrane and subsequent induction of cell death by necrosis, Radiat. Res. 164 (2005) 250–257; DOI: 10.1667/RR3436.1.

17. H. Zhang, V. R. Solomon, C. Hu, G. Ulibarri and H. Lee, Synthesis and in vitro cytotoxicity evaluation of 4-aminoquinoline derivatives, Biomed. Pharmacother. 62 (2008) 65–69; DOI: 10.1016/j.biopha.2007.04.007.

18. V. R. Solomon and H. Lee, Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies, Eur. J. Pharmacol. 625 (2009) 220–233; DOI: 10.1016/j.ejphar.2009.06.063.

19. M. S. Al-Said, M. G. El-Gazzar, M. S. Al-Dosari and M. M. Ghorab, Synthesis, anticancer activity and radiosensitizing evaluation of some new 2-pyridone derivatives, Arzneimittel-Forsch. 62 (2012) 149–156; DOI: 10.1055/s-0031-1299695.

20. P. Fossa, G. Menozzi, P. Dorigo, M. Floreani and L. Mosti, Synthesis and pharmacological characterization of functionalized 2-pyridones structurally related to the cardiotonic agent milrinone, Bioorg. Med. Chem. 11 (2003) 4749–4759; DOI: 10.1016/S0968-0896(03)00528-5.

21. W. Chen, P. Zhan, D. Rai, E. De Clercq, C. Pannecouque, J. Balzarini, Z. Zhou, H. Liu and X. Liu, Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays, Bioorg. Med. Chem. 22 (2014) 1863–1872; DOI: 10.1016/j.bmc.2014.01.054.

22. M. M. Ghorab, Z. H. Ismail, M. Abdalla and A. A. Radwan, Synthesis, antimicrobial evaluation and molecular modelling of novel sulfonamides carrying a biologically active quinazoline nucleus, Arch. Pharm. Res. 36 (2013) 660–670; DOI: 10.1007/s12272-013-0094-6.

23. M. S. Al-Dosari, M. M. Ghorab, M. S. Alsaid and M. Y. Nissan, Discovering some novel 7-chloroquinolines carrying a biologically active benzenesulfonamide moiety as a new class of anticancer agents, Chem. Pharm. Bull. 61 (2013) 50–58; DOI: 10.1248/cpb.c12-00812.

24. M. S. Alsaid, M. S. Bashandy and M. M. Ghorab, Novel quinolines bearing a biologically active trimethoxyphenyl moiety as a new class of antitumor agents, Arzneimittel-Forsch. 61 (2011) 527–531; DOI: 10.1055/s-0031-1296239.

25. M. S. Bashandy, M. S. Al-Said, S. I. Al-Qasoumi and M. M. Ghorab, Design and synthesis of some novel hydrazide, 1, 2-dihydropyridine, chromene derivatives carrying biologically active sulfone moieties with potential anticancer activity, Arzneimittel-Forsch. 61 (2011) 521–526; DOI: 10.1055/s-0031-1296238.

26. M. M. Ghorab, M. S. Al-Said and E. M. El-Hossary, In vitro cytotoxic evaluation of some new heterocyclic sulfonamide derivatives, J. Heterocycl. Chem. 48 (2011) 563–571; DOI: 10.1002/jhet.619.

27. M. S. Al-Said, M. S. Bashandy, S. I. Al-Qasoumi and M. M. Ghorab, Anti-breast cancer activity of some novel 1,2-dihydropyridine, thiophene and thiazole derivatives, Eur. J. Med. Chem. 46 (2011) 137–141; DOI: 10.1016/j.ejm-ech.2010.10.024.

28. M. M. Ghorab, F. A. Ragab, H. I. Heiba, R. K. Arafa and E. M. El-Hossary, Docking study, in vitro anticancer screening and radiosensitizing evaluation of some new fluorine-containing quinoline and pyrimidoquinoline derivatives bearing a sulfonamide moiety, Med. Chem. Res. 20 (2011) 388–400; DOI: 10.1007/s00044-010-9332-3.

29. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenny and M. R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl. Cancer. Inst. 82 (1990) 1107–1112; DOI: 10.1093/jnci/82.13.1107.

30. M. M. Ghorab, M. S. Alsaid, H. A. Ghabour and H.-K. Fun, Synthesis, crystal structure and antitumor activity of novel 2-cyano-N-(quinolin-3-yl) acetamide, Asian J. Chem. 26 (2014) 7389–7392; DOI:10.14233/ajchem.2014.17050.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information

IMPACT FACTOR 2017: 1.071
5-year IMPACT FACTOR: 1.623

CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.362
Source Normalized Impact per Paper (SNIP) 2017: 0.642

Cited By


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 202 202 22
PDF Downloads 104 104 9